Skip to main content

Can-Fite BioPharma Ltd.

CANF
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001536196

No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.

13F holders, Q2 2024

Institutional positions in Can-Fite BioPharma Ltd. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
11
+3 vs. Q1 2024
Shares held
627.8K
+150.2K (+31.5%) vs. Q1 2024
Total value
$1.62M
+$558.9K (+52.7%) vs. Q1 2024
New holders
5
2 more added
Sold out
2
1 more reduced

Compare with Q1 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting CANF on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2024: 11 institutions
Q1 2021: 15 institutionsQ2 2021: 12 institutionsQ3 2021: 12 institutionsQ4 2021: 15 institutionsQ1 2022: 13 institutionsQ2 2022: 12 institutionsQ3 2022: 12 institutionsQ4 2022: 11 institutionsQ1 2023: 9 institutionsQ2 2023: 7 institutionsQ3 2023: 9 institutionsQ4 2023: 9 institutionsQ1 2024: 8 institutionsQ2 2024: 11 institutionsQ3 2024: 12 institutionsQ4 2024: 13 institutionsQ1 2025: 14 institutionsQ2 2025: 16 institutionsQ3 2025: 16 institutionsQ4 2025: 16 institutionsQ1 2026: 14 institutionsQ2 2026: 8 institutions
Value heldQ2 2024: $1.62M
Q1 2021: $1.09MQ2 2021: $1.05MQ3 2021: $2.43MQ4 2021: $626.5KQ1 2022: $472.3KQ2 2022: $464.7KQ3 2022: $380.5KQ4 2022: $262.2KQ1 2023: $843.5KQ2 2023: $167.8KQ3 2023: $179.2KQ4 2023: $638.1KQ1 2024: $1.31MQ2 2024: $1.62MQ3 2024: $1.52MQ4 2024: $185.9KQ1 2025: $193.9KQ2 2025: $950.1KQ3 2025: $952.6KQ4 2025: $271.4KQ1 2026: $428.6KQ2 2026: $149.1K
Institutions holding CANF and their total value by quarter
QuarterHoldersValue
Q2 20268$149.1K
Q1 202614$428.6K
Q4 202516$271.4K
Q3 202516$952.6K
Q2 202516$950.1K
Q1 202514$193.9K
Q4 202413$185.9K
Q3 202412$1.52M
Q2 202411$1.62M
Q1 20248$1.31M
Q4 20239$638.1K
Q3 20239$179.2K
Q2 20237$167.8K
Q1 20239$843.5K
Q4 202211$262.2K
Q3 202212$380.5K
Q2 202212$464.7K
Q1 202213$472.3K
Q4 202115$626.5K
Q3 202112$2.43M
Q2 202112$1.05M
Q1 202115$1.09M

Institutions, Q2 2024

Shares, value and share of portfolio for each institution holding Can-Fite BioPharma Ltd.; share changes are against Q1 2024.

Institutions holding CANF in Q2 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Armistice Capital, LLC518,853$1.34M0.04%+136,055+35.5%Added
Morgan Stanley67,807$174.9K0.00%+12,000+21.5%Added
Rhumbline Advisers15,398$39.7K0.00%−3,084−16.7%Reduced
HRT Financial LP10,790$27.0K0.00%+10,790New
Virtu Financial LLC10,417$27.0K0.00%+10,417New
Fifth Third Bancorp3,000$7.74K0.00%00.0%Unchanged
National Bank of Canada600$1.55K0.00%00.0%Unchanged
Citigroup Inc553$1.43K0.00%00.0%Unchanged
Activest Wealth Management200$5160.00%+200New
Advisor Group Holdings, Inc.185$4770.00%+185New
TD Waterhouse Canada Inc.20$520.00%+20New
Citadel Advisors LLC0$00.00%−14,171−100.0%Sold out
UBS Group AG0$00.00%−2,172−100.0%Sold out